Effect of evolocumab on lipoprotein particles

Slides:

Advertisements

Similar presentations

Lipoprotein Management. Step 1: Assess clinical CHD risk (Very-High, High, Moderately-High, Moderate, Low Risk) Step 2: Establish goals of therapy appropriate.

Advertisements

Relationship of LDL-C & LDL-P. Lipoprotein Particles LipoScience 2007 NON-POLAR LIPID CORE Cholesterol Ester Triglyceride POLAR SURFACE COAT Phospholipid.

Lipoprotein Structure and Function

Weng TC, et al. J Clin Pharm Ther 2010;35:

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

Lipoproteins Clusters of lipids associated with proteins that serve as transport vehicles for lipids in the lymph and blood.

Lipoproteins/Particles

Clinical diagnostic biochemistry - 8

Slide Source Kaplan-Meier Curve of Time to Primary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators.

ACE inhibitors, ARBs and Statins in COPD: High- and Low-Risk Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:

Parameters BD PP CP TC (mg. dl-l) ± * ± 5.8

From: Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects J Am Coll Cardiol. 2012;60(20): doi: /j.jacc

M.Sc. in Pharmacy/Clinical Laboratory Sciences

Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride.

Atherosclerosis, Plaque Imaging

Clinical Characteristics

Transport of lipids Title slide - the transport of lipids. Important because they aren’t water soluble.

Oxford Niacin Trial.

by John T. Wilkins, Hongyan Ning, Neil J. Stone, Michael H

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Figure 7 Mendelian randomization of overlapping exposures

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Kendra K. Kattelmann, PhD, RD: South Dakota State University (SDSU)

Volume 93, Issue 6, Pages (June 2018)

Atorvastatin 20 mg (n=25 lesions) Atorvastatin 5 mg (n=25 lesions)

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

عنوان دوره آموزشی: کاهش مصرف روغن و نمک

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial Erik S.G. Stroes, MD, PhD, Andrey.

Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF

Nat. Rev. Cardiol. doi: /nrcardio

Konstantinos C. Siontis et al. JACEP 2016;2:

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Joshua A. Bell et al. JACC 2018;72:

II. assessment of dyslipidemias

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Description of studies for pooled analyses

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Screening, Lipid Stabilization, and Placebo Run-in

OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Subject Characteristics

Figure 1 The major pathways of lipid metabolism

Kendra K. Kattelmann, PhD, RD: South Dakota State University (SDSU)

Clinical Characteristics and Atheroma Burden of Subjects at Baseline Stratified According to Gender Nicholls SJ. et al. J Am Coll Cardiol 2007;49:

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Body mass, BMI, plasma lipids, lipoproteins, and glucose homeostasis at baseline, and following placebo and rosuvastatin periods Dmitri Sviridov et al.

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Baseline Patients with coronary artery disease (CAD) and high (n=98) versus normal (n=1512) high-density lipoprotein (HDL) levels Doreen DeFaria Yeh, et.

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Assembly and secretion of apoB100- containing lipoproteins

Disposition of Patients in the Atherogenic Dyslipidemia Study

Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Schematic representation of dyslipidaemia of metabolic syndrome.

Characteristics of included studies

Obese gestational diabetes mellitus (GDM) women demonstrate significant dyslipidemia at 26 weeks of gestation compared to obese women without diabetes.

Lars E. Laugsand et al. BTS 2016;j.jacbts

Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.

Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),

Monitoring for diabetic complications in home care baseline data

Change in markers of glycometabolism and cardiovascular risk profile.

Absolute mortality difference Change in LVEF from baseline

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Amir A. Mahabadi et al. JIMG 2017;10:

Increase of physical activity over time associated with lower HF risk

Individual lipid measures for high-carbohydrate (n=10) and low-carbohydrate (n=10) ultra-endurance athletes. Individual lipid measures for high-carbohydrate.

© The Author(s) Published by Science and Education Publishing.

Differences in changes in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides (expressed as mg/dL) between patients with hyperlipidaemia.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Medication intensity (ALLP) changes between baseline and 6 months, by (not) being low-density lipoprotein-cholesterol (LDL-C) target at baseline for nurse-coordinated.

Presentation transcript:

Effect of evolocumab on lipoprotein particles Mean % change from baseline to week 52 (95%CI) Total LDL-p Total HDL-p Total VLDL-p/ chylomicron IDL-p Evolocumab (N=294) -44.1 (-47.2 to -40.9) 9.4 (7.5-11.4) -15.3 (-39.3 to 15.4) -36.2 (-69.8 to 22.0) Placebo (N=236) 6.4 (2.9 – 9,9) -0.1 (-1.6 to 1.4) -0.3 (-26.3 to 31.7) 0 (-47.4 to 87.5) P value P <0.0001 P <0.001 CI: confidence interval; QM: once every month; LDL-p: low-density lipoprotein particle concentration; HDL-p: high-density lipoprotein particle concentration; VLDL-p: very low-density lipoprotein particle concentration; IDL-p: intermediate-density lipoprotein particle concentration; Toth PP, et al. Am J Cardiol 2018;121:308–314